The impact of pre-existing cancer on survival of prostate cancer patients

A population-based study

Yuan Zhou, MS,a,b, Han Guan, MD,b,c, Yong Fu, MS,a,b, Likai Mao, MS,a,b, Jiyue Ge, MS,a,b, Lutan Liu, MS,a,b, Lei Cheng, MD,e,f, Chao Guan, MS,a,b,*

Abstract
Prostate cancer (PCa) is the second most common malignant tumors for male patients worldwide. However, whether a history of pre-existing cancer cases may affect the survival of prostate cancer patients is still not fully understood.

We identified patients diagnosed with PCa between 2000 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) linked database. We further made propensity score matching and then compared all-cause and cancer-specific survival between patients with and those without a pre-existing cancer. Cox proportional hazards models and Kaplan-Meier analysis were used for survival comparison.

A total of 153,255 patients with PCa were included for analysis, of whom 5939 had a history of pre-existing cancer, including hematologic and lymph (11%), intestine (19%), urinary system (36%), head and neck (9%), lung (5%), skin (12%), and others (8%). Patients with a pre-existing cancer had a worse prognosis compared with those without a pre-existing cancer [all-cause death: hazard ratio (HR) = 2.74, \( P < .001 \); cancer-specific death: \( HR = 3.98, P < .001 \)]. Importantly, cancers in urinary bladder prior to PCa had a most adverse impact on all-cause (HR = 5.00, \( P < .001 \)) and cancer-specific death risk (HR = 10.45, \( P < .001 \)). Time between the pre-existing cancer and PCa had a dose-dependent effect on survival of PCa patients, with a decreased death risk as the increase of the interval time.

Pre-existing cancer has a negative impact on the prognosis of patients with PCa, which is most evident in the presence of a pre-existing urinary bladder cancer. Our results provide epidemiologic evidence with low between-group bias, large sample size, and long-term follow-up, highlighting the need for site- and interval-time-based clinical management for patients with PCa who had a pre-existing cancer.

Abbreviations: CI = confidence interval, HR = hazard ratio, PCa = prostate cancer, PSA = prostate-specific antigen, PSM = propensity score matching, RP/Ur/UB = renal pelvis, ureter, or urinary bladder, SEER = Surveillance Epidemiology and End Results, SPM = second primary malignancy.

Keywords: bladder cancer, prostate cancer, second primary cancer, SEER, survival

1. Introduction

Prostate cancer (PCa) is the second most common cancer worldwide, and the fifth leading cause of cancer-related deaths in men worldwide.[1] There is a notable difference in PCa incidence among different regions and races, with a highest incidence in the United States and a lowest incidence in Asia.[2] From 1980s, extensive prostate specific antigen (PSA) detection largely facilitate the screening of prostate cancer.[3] Because of a high rate of over diagnosis induced by PSA screening,[4,5] PSA density of transition zone, free/total PSA ratio, p2PSA and Prostate Health Index as well as prostate-specific membrane antigen have also been tried to be introduced into clinical management to improve PCa screening.[6–9] At the same time, PCa patients were greatly benefited from the development of drug therapy and radiotherapy.[10–13] With the advances in both the screening and therapy, the 5-year relative survival rate reached almost 100% for PCa patients with localized disease and 28% for those harboring a distant disease.[13]

With frequent early diagnosis and advances in cancer treatments in recent years, about 15.1 million cancer survivors lived in the United States in 2016 and the number are expected to increase to 20.3 million by 2026.[13] Survivors of cancer patients are at
high risk of developing a second primary cancer (SPM). SPM as a serious long-term complication, largely increased the death risk of cancer patients. According to follow-up analysis, about 8% cancer patients developed a SPM in patients with first incident cancers. In patients with only one primary cancer, the cancer mortality rate was approximately 52%. Among those who carried a SPM, 13% died of the initial, and 55%, however, died of the SPM, indicating that SPMs had a synergistically fatal impact on the patients. For all types of SPMs, lung cancer was recognized as the most common and deadliest cancer, and survivors of bladder cancer showed the highest incidence of SPMs. According to a study in France, males have the risk of SPM than females. Regional differences can also lead to different incidence of SPMs, likely due to differences in dietary habits and genetic factors. In addition, tobacco and alcohol were recognized as the 2 major factors that accounted for the increased risk of SPM.

As reported by analysis of SPM incidence from Surveillance, Epidemiology, and End Results (SEER) database, survivors of colorectal cancer, lung cancer, kidney cancer and melanoma patients had a relatively high risk of carrying PCa as a SPM, indicating a high incidence of suffering cancers prior to PCa. However, to our best knowledge, the impact of pre-existing cancers on survival of PCa patients is still unclear. Therefore, it is necessary to assess the prevalence of cancers prior to PCa and their role in mediating survival of PCa patients, in the light of the widely accessed and worldwide epidemiological data provided by SEER database.

2. Materials and methods

2.1. Data acquisition

Data used for analysis in the present study were obtained from SEER database [SEER 18 Regs Research Data, (1973–2014 varying); Version 8.3.4]. The SEER database published the population-based incidence and survival data of cancer patients, covering about 28% of cancer registries from the United States. Clinical information provided by the SEER database largely facilitates clinical cancer research.

2.2. Study population

This study included patients diagnosed with PCa between year of 2000 and 2014. All cancer patients had pathologically confirmed diagnosis, and we included only PCa patients with the most common pathological subtype, adenocarcinoma, to minimize the pathological bias. The available information on race, age, stage, surgery, PSA, Gleason score, tumor size, grade, and marital status were prerequisites for the inclusion of the patients. We excluded the patients with blank information above mentioned. PCa was defined as the first primary cancer if no primary cancer were detected for patients as indicated by SEER database. Patients were deemed as to have suffered a pre-existing cancer, if there was one type of cancer out of prostate that prior to the diagnosis of PCa.

2.3. Statistical analysis

The prevalence and stage of pre-existing cancer, site of pre-existing cancer, and interval time between prostate and pre-existing cancer were reported in the present study.

To balance the clinical variables and reduce the statistical bias as more as possible, we made a propensity score matching (PSM) between patients who had a pre-existing cancer and those who did not. The information on race, age, stage, surgery, PSA, Gleason score, tumor size, grade and marital status were propensity matched. Then, the matched data were used for survival comparison. We used PSM-adjusted Kaplan–Meier analysis to compare survival between patients with and without a pre-existing cancer. All-cause and cancer-specific deaths were primary end-points in the presents study. For all-cause survival analysis, alive patients were considered as censored data. For cancer-specific survival analysis, alive patients and those who died for the reasons unrelated to cancer were considered as censored data during survival analysis. Cox proportional hazards regression models were used for the comparison of all-cause cancer death risk and cancer-specific death risk among patients.

All statistical analyses were achieved by R software (Version 3.4.0, R Foundation, Vienna). Two-tailed P value <.05 was considered as statistical significance.

Ethical approval: All data in our study were obtained from SEER database with the aims of research, thus this study does not contain any human participants or animals collected by any of the authors.

3. Results

A total of 153,255 PCa patients diagnosed between 2000 and 2014 were included in the present study. Among these patients, 5939 PCa patients had a history of pre-existing cancer. The type of pre-existing cancer contained hematologic and lymph (11%), intestine (19%), urinary system (36%), head and neck (9%), lung (5%), skin (12%) and others (8%). 61% (n=3650) of pre-existing cancers were staged as localized or in situ, and only 7% (n=443) were distant disease. 86% (n=5107) of pre-existing cancers were diagnosed within 5 years prior to PCa. The average time between the pre-existing cancer and PCa was about 3 years. About 5% PCa patients (n=7,329) with one primary PCa and 16% PCa patients (n=925) who had a pre-existing cancer, were died of cancer-specific reasons, respectively. Table 1 listed the available information for all patients and those with a pre-existing cancer on race, age, sex, stage, surgery, PSA, Gleason score, tumor size, grade, and marry status. Distribution of all variables did not differ between groups after adjustment for propensity matching (P >.05 for all).

In PSM-adjusted K-M curves, PCa patients with a pre-existing cancer had a worse all-cause (5-year survival, 72.65% vs 91.67%, P <.001 for all) and cancer-specific survival (5-year survival, 86.73% vs 97.41%, P <.001 for all) in comparison with those with only one primary PCa (Figure 1). In K-M analysis stratified by the type of pre-existing cancer, cancers in urinary bladder prior to PCa had a most adverse impact on survival of PCa patients (For pre-existing cancer in urinary bladder cancer, 5-year all-cause survival: 61.79% vs 97.92%, P <.001 for all, Figure 2).

We further made comparisons of all-cause death risk and cancer-specific death risk between groups by PSM-adjusted Cox regression models. We found that a pre-existing cancer increased the all-cause death risk and cancer-specific death risk by 174% [hazard ratio (HR)=2.74, 95% confidence interval (CI)=2.63–2.87, P <.001] and 298% (HR=3.98, 95%CI=3.70–4.27, P <.001), respectively, for PCa patients (Table 2). Interestingly, time between the pre-existing cancer and PCa had a dose-
**Table 1** Baseline characteristics of PCa patients included from SEER data cohort (N = 153,255) and between-group comparisons (No pre-existing cancer vs pre-existing cancer).

| Patient characteristics | No. of total patients | No. of patients with pre-existing cancer | Unadjusted P value | PSM-adjusted P value |
|-------------------------|-----------------------|----------------------------------------|-------------------|----------------------|
| Age, years              |                       |                                        |                   |                      |
| Age < 60                | 42,391                | 983                                    | <.001             | .9750                |
| 60 ≤ Age < 80           | 100,860               | 4250                                   |                   |                      |
| Age ≥ 80                | 10,004                | 706                                    |                   |                      |
| Race                    |                       |                                        | <.001             | .9776                |
| White                   | 121,880               | 5074                                   |                   |                      |
| Black                   | 22,794                | 615                                    |                   |                      |
| Other                   | 8581                  | 250                                    |                   |                      |
| Marriage status         |                       |                                        | <.001             | .8771                |
| Married                 | 117,822               | 4567                                   |                   |                      |
| Sep/Div/Wid             | 19,414                | 833                                    |                   |                      |
| Single                  | 16,019                | 539                                    |                   |                      |
| PSA                     |                       |                                        | <.001             | .8339                |
| PSA ≤ 10                | 2016                  | 162                                    |                   |                      |
| 10 < PSA ≤ 50           | 44,434                | 1456                                   |                   |                      |
| PSA > 50                | 106,805               | 4321                                   |                   |                      |
| Gleason                 |                       |                                        | <.001             | .7873                |
| Gleason < 5             | 907                   | 67                                     |                   |                      |
| 5 ≤ Gleason < 8         | 132,210               | 5064                                   |                   |                      |
| Gleason ≥ 8             | 20,138                | 808                                    |                   |                      |
| Tumor size, mm          |                       |                                        | <.001             | .3516                |
| Size < 4                | 82,840                | 3456                                   |                   |                      |
| 4 ≤ Size                | 70,415                | 2483                                   |                   |                      |
| Grade                   |                       |                                        | <.001             | .8531                |
| Well                    | 994                   | 73                                     |                   |                      |
| Moderately              | 73,361                | 3009                                   |                   |                      |
| Poor                    | 78,525                | 2841                                   |                   |                      |
| Undifferentiated        | 375                   | 16                                     |                   |                      |
| Stage                   |                       |                                        | <.001             | .9581                |
| Localized               | 127,486               | 5149                                   |                   |                      |
| Regional                | 22,699                | 651                                    |                   |                      |
| Distant                 | 3070                  | 139                                    |                   |                      |
| Surgery                 |                       |                                        | .0151             | .8544                |
| Yes                     | 77,447                | 2909                                   |                   |                      |
| No                      | 75,808                | 3030                                   |                   |                      |
| Death status            |                       |                                        | <.001             |                      |
| Alive                   | 128,758               | 3624                                   |                   |                      |
| Death                   | 24,497                | 2315                                   |                   |                      |
| Cause of death          |                       |                                        | <.001             |                      |
| By cancer               | 7299                  | 925                                    |                   |                      |
| Other cause or alive    | 145,926               | 5014                                   |                   |                      |
| Total                   | 153,255               | 5939                                   |                   |                      |

*Comparisons between groups after adjustment for propensity matching score.

PCa = prostate cancer, Sep/Div/Wid = separated, divorced, or widowed.

**Figure 1.** PSM-adjusted comparison for all-cause (A) and cancer-specific survival (B) between PCa patients with and without a pre-existing cancer. PCa = prostate cancer, PSM = propensity score matching.
Table 2

The comparison of all-cause death risk and all cancer-specific death risk between PCa patients with and without a pre-existing cancer.

| Pre-existing cancer diagnosis (vs None) | All-cause HR (95% CI) | \( P \) value | Cancer-specific HR (95% CI) | \( P \) value |
|---------------------------------------|-----------------------|---------------|-----------------------------|---------------|
| Site of pre-existing cancer            |                       |               |                             |               |
| All site                              | 2.74 (2.63–2.87)      | <.001         | 3.98 (3.70–4.27)            | <.001         |
| Hematologic/lymph                     | 2.44 (2.14–2.79)      | <.001         | 3.84 (3.12–4.73)            | <.001         |
| Intestine                             | 1.86 (1.69–2.06)      | <.001         | 1.82 (1.51–2.20)            | .001          |
| Urinary system                        | 4.15 (3.88–4.43)      | <.001         | 8.15 (7.39–9.02)            | <.001         |
| Kidney                                | 2.17 (1.83–2.59)      | <.001         | 3.02 (2.22–4.10)            | <.001         |
| RP/Ur/UB                              | 4.88 (4.55–5.24)      | <.001         | 10.16 (9.14–11.29)          | <.001         |
| Renal pelvis                          | 2.31 (1.15–4.62)      | .018          | 1.64 (0.23–11.67)           | .622          |
| Ureter                                | 2.20 (0.99–4.63)      | .054          | 1.99 (0.28–11.29)           | .493          |
| Urinary bladder                       | 5.00 (4.65–5.37)      | <.001         | 10.65 (9.40–11.62)          | <.001         |
| Head/Neck                             | 2.57 (2.23–2.97)      | <.001         | 2.91 (2.27–3.74)            | <.001         |
| Lung                                  | 4.23 (3.64–4.91)      | <.001         | 6.68 (5.37–8.31)            | <.001         |
| Skin                                  | 1.52 (1.31–1.77)      | <.001         | 1.18 (0.86–1.61)            | <.001         |
| Other                                 | 2.82 (2.45–3.26)      | <.001         | 4.59 (3.72–5.65)            | <.001         |
| Stage of pre-existing cancer          |                       |               |                             |               |
| Unknown                               | 2.36 (2.08–2.67)      | <.001         | 2.97 (2.42–3.64)            | <.001         |
| In situ                               | 2.18 (1.90–2.51)      | <.001         | 1.94 (1.45–2.60)            | <.001         |
| Localized                             | 2.27 (2.13–2.42)      | <.001         | 2.68 (2.40–3.00)            | <.001         |
| Regional                              | 4.67 (4.31–5.08)      | <.001         | 9.18 (8.17–10.32)           | <.001         |
| Distant                               | 4.15 (3.62–4.74)      | <.001         | 8.06 (7.54–10.66)           | <.001         |
| Interval time of pre-existing cancer  |                       |               |                             |               |
| < 1 year                              | 6.27 (5.73–6.88)      | <.001         | 14.98 (13.21–16.99)         | <.001         |
| 1–3 years                             | 2.68 (2.53–2.84)      | <.001         | 4.10 (3.73–4.50)            | <.001         |
| 3–5 years                             | 2.03 (1.84–2.24)      | <.001         | 2.03 (1.70–2.43)            | <.001         |
| > 5 years                             | 2.01 (1.77–2.29)      | <.001         | 1.64 (1.27–2.11)            | <.001         |

Note: Cox regression was used for the death risk comparison according to site and stage of the pre-existing cancers, as well as the interval time between the pre-existing cancer and PCa. All comparisons were adjusted for propensity matching score.

CI = confidence interval, \( \text{HR} \) = hazard ratio, RP/Ur/UB = renal pelvis, ureter, or urinary bladder.

Figure 2. The comparison of all-cause survival between PCa patients with and without a pre-existing cancer, adjusted by PSM score and stratified by the pre-existing cancer type. (A) No pre-existing cancer vs pre-existing hematologic and lymph cancer; (B) No pre-existing cancer vs pre-existing intestine cancer; (C) No pre-existing cancer vs pre-existing urinary system cancer; (D) No pre-existing cancer vs pre-existing head and neck cancer; (E) No pre-existing cancer vs pre-existing lung cancer; (F) No pre-existing cancer vs pre-existing skin cancer; (G) No pre-existing cancer vs pre-existing other cancer; (H) No pre-existing cancer vs pre-existing urinary bladder cancer. PCa = prostate cancer, PSM = propensity score matching.
dependent effect on death risk of PCa patients, with a decreased all-cause death and cancer-specific death risks as the increase of the interval time (Table 2). In line with the trend toward poorest survival in the univariate Kaplan–Meier test, pre-existing cancers in urinary bladder cancers was also a most unfavorable factor for all-cause and cancer-specific death risk which was increased by 4.00-fold (HR = 5.00, 95%CI=4.63–5.37, P < .001) and 9.45-fold (HR = 10.45, 95%CI=9.40–11.62, P < .001), respectively, and followed by lung cancer, with death risk increased by 3.23-fold (HR = 4.23, 95%CI=3.64–4.91, P < .001) and 5.68-fold (HR = 6.68, 95%CI=5.37–8.31, P < .001), respectively (Table 2). However, renal pelvis and ureter cancers as the 2 other important sites of urinary system cancers prior to PCa seemed to be unable to affect the cancer-specific death risk of PCa patients (P > .05 for all), despite a slight increased all-cause death risk was observed in presence of pre-existing renal pelvis cancer (HR = 2.31, 95%CI = 1.15–4.62, P = 0.018, Table 2). In subgroup analysis by pathological type of pre-existing cancer, we found that a pre-existing nontransitional bladder cancer had a more adverse impact on death risk of prostate cancer, followed by the pre-existing cancer of squamous cell lung carcinoma, in terms of either all-cause (for pre-existing nontransitional bladder cancer, HR = 6.83, 95%CI = 4.39–9.46, P < .001 and squamous cell lung carcinoma, HR = 5.15, 95%CI =3.90–6.30; P < .001) or cancer-specific survival (for pre-existing non-transitional bladder cancer, HR = 20.24, 95%CI =12.91–31.71; P < .001 and squamous cell lung carcinoma, HR = 8.74, 95%CI=6.04–12.64; P < .001).

However, because of the number of patients with specialize pathological type of pre-existing cancer, we limited (e.g., for pre-existing nontransitional bladder cancer, n = 66; and squamous cell lung carcinoma, n = 73), further larger studies are warranted to validate our subgroup findings.

4. Discussion

For PCa patients, our study revealed that a pre-existing cancer increased the all-cause death risk and cancer-specific death risk by 1.74-fold and 2.98-fold, respectively. Importantly, the urinary bladder cancer and lung cancer were found in the present study as 2 leading types of pre-existing cancer responsible for poor survival, compared with other types of pre-existing cancer, that mostly contribute to the overall death risk increased by 4.00 and 3.23, respectively. However, pre-existing skin cancer had a minimum impact on cancer related death risk, and only a slight increase of death risk was observed in presence of the pre-existing kidney cancer for PCa patients. These results have important implications on the involvement of pre-existing cancer in clinical management of prostate cancer patients in a site-dependent manner.

In the present study, we combined the pre-existing renal pelvis cancer, ureter cancer, and urinary bladder cancer as the RP/Ur/UB, in order to analysis the collective effect of these 3 types of pre-existing cancers on survival analysis and death risk for PCa patients. The single survival impact of pre-existing renal pelvis cancer, ureter cancer, and urinary bladder cancer, respectively, were also analyzed, and the HR for both all-cause and cancer-specific deaths was lower or with an insignificant trend for both the PCa patients with renal pelvis and those with ureter pre-existing cancer types, but became much higher and significant in the presence of a pre-existing urinary bladder cancer. Also recognized, transitional cell carcinoma is the shared major pathological type in renal pelvis cancer, ureter cancer, and urinary bladder cancer, which is a symbol of a similar genetic background for these 3 types of cancer. Therefore, it is more biological plausible if the prognosis was similar to each other among the 3 types of pre-existing cancer carrier patients. However, the prominent adverse effect on prognosis induced by the pre-existing urinary bladder, the renal pelvis cancer and ureter cancer, suggested that the coexistence of urinary bladder and PCa was the deadest factor that contributes to the poor survival of the patients. The potential mechanism underlying this observation needs further investigations.

Bladder cancer was found to be the most common cancer, with a prevalence of 28% (n = 1642), prior to PCa in the present study, similar to previous study which reported a high frequency of double primary cancers of the bladder and prostate. Moreover, only 1% (n = 22) of patients with a pre-existing urinary bladder cancer had the same pathological type as prostate cancer. According to the age-adjusted incidence, bladder cancer patients had 18 times greater rate to suffer PCa, and PCa patients had 19 times greater risk to carry bladder cancer, when compared with the absolute PCa and bladder cancer incidence in the general population, respectively. Moreover, the incidence of prostate cancer followed by invasive bladder cancer was reported by another report to be as high as 70%. The coexistence of bladder cancer and PCa was of high presence, importantly, might result in a poor prognosis, which was in accordance with our study in which we observed a prominent adverse impact of bladder cancer on survival of PCa patients. As we known, PCa and bladder cancer may share a similar carcinogenic process in the genetic and protein level, such as P53, nRb, and UROC28 protein over-expression, underlying our observation that a pre-existing bladder cancer might synergistically with PCa to have increased the death risk of patients. Another molecular epidemiological evidence revealed that genetic variants of genes involved in DNA repair and N-acetyltransferase were shared causes of increased risk of both cancers. Therefore, according to these results, we recommended a close surveillance of bladder cancer prior to PCa to advance the treatment decision for PCa patients.

In our study, next to bladder cancer, pre-existing lung cancer had the second most adverse impact on survival in PCa patients. Lung cancer is characterized by particularly lethal, with 5-year survival rate about 55%, 27% and 4% for localized, regional and distant disease, respectively. How- ever, according to cancer statistics, PCa was recognized as the most common SPM for lung cancer patients. The high incidence of second primary PCa may be caused by its high prevalence in men, because the annual excess risk and observed annual risk for second primary PCa was lower than the average for SPM in lung cancer patients, indicating that lung cancer and PCa might have no direct relationship like that between bladder cancer and PCa. Moreover, unlike PCa and bladder cancer that shared similar genetic background in cancer etiology, few literature reported that there was a specific link between lung cancer and PCa. Collectively, in our study, the poor prognosis in patients with lung cancer prior to PCa might be only a reflection of poor survival and prognosis of lung cancer patients.

Interestingly, based on the results of the present study, the dose-dependent effect of interval time between pre-existing cancer and PCa on death risk of the patients, with a trend toward better prognosis with the increase of the interval time, post a necessary to set a time-dependent model to make reasonable clinical management for PCa patients who suffered a pre-existing cancer.
There are some limitations in this study. First, the treatment of pre-existing cancer such as radiation and chemotherapy may affect the risk of occurrence and survival of SPM,[23] and the smoking history of patients may affect the survival of patients, but the missing information on treatment and smoking history may introduce bias to the present study. Second, the number of patients in some specified sites or pathological type of the pre-existing cancer were limited, leading to the deficient in calculating the specified effect of some pre-existing cancers on survival of PCA cancer patients. Lastly, although a strict matching method was adopted to avoid between-group bias, because of the retrospective design in nature of the present study, large prospective studies are warranted to validate our results.

5. Conclusions
In conclusion, pre-existing cancer has an adverse impact on survival of PCA patients, and this adverse impact is more evident in presence of pre-existing cancers of urinary bladder. Interval time between pre-existing cancer and PCA had a dose-dependent effect with a trend toward favorable prognosis of PCA patients with a pre-existing cancer. The time between pre-existing cancer and PCa had a dose-dependent effect with a trend toward favorable prognosis of PCa patients as the increase of the interval time. Our results provide sufficient evidence on the role the pre-existing cancer may play in mediating the survival of PCA patients, raising the necessary for the site- and interval-time-depended individualized clinical management for PCA patients with a pre-existing cancer.

Author contributions
Conceptualization: Chao Guan, Lei Cheng.
Data curation: Yuan Zhou, Han Guan.
Formal analysis: Yuan Zhou, Lei Cheng.
Funding acquisition: Chao Guan.
Methodology: Yuan Zhou, Han Guan.
Supervision: Chao Guan, Lei Cheng.
Validation: Yong Fu, Likai Mao, Gi-Yue Ge, Lutan Liu.
Writing – original draft: Yuan Zhou, Han Guan.
Writing – review & editing: Chao Guan, Lei Cheng.

References
[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
[2] Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. Jap J Clin Oncol 2007;37:356–7.
[3] Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548–52.
[4] Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014;311:1143–9.
[5] Drasina G, Erzioni B, Tsiodrak A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–83.
[6] Djavan B, Zlotra A, Kratik C, et al. PSA, PSA density, PSA density of transition zone, free/totol PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 1999;54:117–22.
[7] Catalona WJ, Parin AW, Sanda MG, et al. A multicenter study of [–2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1630–5.
[8] Ng CF, Chiu PK, Lam NY, et al. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10ng/mL. Int Urol Nephrol 2014;46:711–7.
[9] Yao V, Farwani A, Maier C, et al. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 2008;68:9070–7.
[10] Cooperberg MR1, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117–23.
[11] Denham JW1, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451–9.
[12] Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107–18.
[13] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2016;66:271–89.
[14] Demark-Wahnefried W, Aziz NM, Rowland JH, et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005;23:5814–30.
[15] Donin N, Filsion C, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 2016;122:3075–86.
[16] Mariotto AB, Rowland JH, Ries LA, et al. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007;16:566–71.
[17] Jégu J, Colonna M, Daubisse-Marlac L, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 2014;14:94.
[18] Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review. National Cancer Institute, Bethesda, MD:2015.
[19] Chun TY. Coincidence of bladder and prostate cancer. J Urol 1997;157:63–7.
[20] Mahadevia PS, Koss LG, Tar IJ. Prostatic involvement in bladder cancer. Prostate mapping in 20 cystoprostatectomy specimens. Cancer 1986;58:2096–102.
[21] Khanal A, Budhathoki N, Singh VP, et al. Second primary malignancy in bladder carcinoma—a population-based study. Anticancer Res 2017;37:2033–6.
[22] Kinoshita Y, Singh A, Rovito PM Jr, et al. Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Canc 2004;3:83–6.
[23] Sinik Z, Alkbay T, Ataoglu O, et al. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Int J Urol 1997;4:546–51.
[24] Singh A, Jones RF, Friedman H, et al. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. Anticancer Res 1999;19:5413–7.
[25] An G, Ng AY, Meka CS. Cloning and characterization of UROC28, a folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 2008;68:9070–7.
[26] Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:566–71.
[27] Mao R, Chen T, Zhou F, et al. The burdens of lung cancer involved in bladder, prostate, and renal carcinomas. Int J Urol 1997;4:546–51.
[28] Singh A, Jones RF, Friedman H, et al. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. Anticancer Res 1999;19:5413–7.